{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:29:38Z","timestamp":1773160178914,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ijrobp.2020.08.055","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T11:22:59Z","timestamp":1598613779000},"page":"220-230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Risk of Pneumonitis and Outcomes After Mediastinal Proton Therapy for Relapsed\/Refractory Lymphoma: A PTCOG and PCG Collaboration"],"prefix":"10.1016","volume":"109","author":[{"given":"Yolanda D.","family":"Tseng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradford S.","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Dedeckova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chirayu G.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine E.","family":"Hill-Kayser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Maity","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy P.","family":"Mendenhall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond B.","family":"Mailhot Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torunn I.","family":"Yock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujith","family":"Baliga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clayton B.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen M.","family":"Winkfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranshu","family":"Mohindra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lane R.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William F.","family":"Hartsell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Plastaras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2020.08.055_bib1","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib2","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib3","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response\u2013adapted treatment in stage I and II Hodgkin lymphoma: Final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib4","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1200\/JCO.2015.65.4582","article-title":"Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma: Final and long-term analysis of Southwest Oncology Group Study S8736","volume":"34","author":"Stephens","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"Chop-like chemotherapy plus rituximab versus chop-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib6","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-chop to standard chop chemotherapy in DLBCL patients: A study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib7","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0360-3016(96)00277-5","article-title":"High-dose therapy and autologous bone marrow transplantation for relapsed\/refractory Hodgkin\u2019s disease: The impact of involved field radiotherapy on patterns of failure and survival","volume":"36","author":"Poen","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.clml.2016.09.008","article-title":"Potential benefit of involved-field radiotherapy for patients with relapsed-refractory Hodgkin\u2019s lymphoma with incomplete response before autologous stem cell transplantation","volume":"17","author":"Levis","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib10","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1083-8791(01)80012-4","article-title":"The impact of external beam radiation therapy prior to autologous bone marrow transplantation in patients with non-Hodgkin\u2019s lymphoma","volume":"7","author":"Friedberg","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib11","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1200\/JCO.2007.15.4773","article-title":"Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: Long-term disease control and toxicity","volume":"26","author":"Hoppe","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijrobp.2017.05.007","article-title":"Role of consolidative radiation therapy after autologous hematopoietic cell transplantation for the treatment of relapsed or refractory Hodgkin lymphoma","volume":"99","author":"Wilke","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib13","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.ijrobp.2005.09.030","article-title":"Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin\u2019s lymphoma","volume":"64","author":"Martens","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib14","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1016\/j.ijrobp.2012.04.007","article-title":"Role of salvage radiation therapy for patients with relapsed or refractory hodgkin lymphoma who failed autologous stem cell transplant","volume":"84","author":"Goda","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib15","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/cncr.30482","article-title":"A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed\/refractory hodgkin lymphoma undergoing autologous stem cell transplantation","volume":"123","author":"Milgrom","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib16","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/(SICI)1520-6823(1999)7:3<186::AID-ROI8>3.0.CO;2-2","article-title":"Value of radiation therapy in the management of chemoresistant intermediate grade non-Hodgkin\u2019s lymphoma","volume":"7","author":"Aref","year":"1999","journal-title":"Radiat Oncol Investig"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijrobp.2014.09.041","article-title":"Rates and durability of response to salvage radiation therapy among patients with refractory or relapsed aggressive non-Hodgkin lymphoma","volume":"91","author":"Tseng","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib18","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma","volume":"34","author":"van Nimwegen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib19","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1001\/jama.1993.03510160067031","article-title":"Factors affecting late mortality from heart disease after treatment of Hodgkin\u2019s disease","volume":"270","author":"Hancock","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib20","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib21","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/jnci\/djr533","article-title":"Second malignant neoplasms and cardiovascular disease following radiotherapy","volume":"104","author":"Travis","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib22","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2006.09.0936","article-title":"Long-term solid cancer risk among 5-year survivors of Hodgkin\u2019s lymphoma","volume":"25","author":"Hodgson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib23","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0959-8049(98)00304-9","article-title":"Thoracic radiation therapy before autologous bone marrow transplantation in relapsed or refractory Hodgkin\u2019s disease. PMH Lymphoma Group, and the Toronto Autologous BMT Group","volume":"35","author":"Tsang","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib25","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijrobp.2011.05.078","article-title":"Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapy","volume":"83","author":"Fox","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijrobp.2015.02.010","article-title":"Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma","volume":"92","author":"Pinnix","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib27","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.ijrobp.2014.04.029","article-title":"Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: Results of a phase 2 study","volume":"89","author":"Hoppe","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib28","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1080\/0284186X.2016.1197422","article-title":"Proton therapy patterns-of-care and early outcomes for Hodgkin lymphoma: Results from the proton collaborative group registry","volume":"55","author":"Hoppe","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib29","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/pbc.26044","article-title":"Proton therapy for pediatric Hodgkin lymphoma","volume":"63","author":"Wray","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib30","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1093\/annonc\/mdx287","article-title":"Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma","volume":"28","author":"Hoppe","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib31","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.3109\/10428194.2015.1014364","article-title":"Proton therapy in the management of non-Hodgkin lymphoma","volume":"56","author":"Sachsman","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib32","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ijrobp.2017.05.004","article-title":"Evidence-based review on the use of proton therapy in lymphoma from the particle therapy cooperative group (PTCOG) lymphoma subcommittee","volume":"99","author":"Tseng","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib33","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3109\/0284186X.2013.850739","article-title":"Pulmonary damage in Hodgkin\u2019s lymphoma patients treated with sequential chemo-radiotherapy: Predictors of radiation-induced lung injury","volume":"53","author":"Cella","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib34","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijrobp.2006.03.063","article-title":"Clinical dose-volume histogram analysis in predicting radiation pneumonitis in Hodgkin\u2019s lymphoma","volume":"66","author":"Koh","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib35","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/j.prro.2018.01.007","article-title":"Radiation pneumonitis in pediatric Hodgkin lymphoma patients receiving radiation therapy to the chest","volume":"8","author":"Lewis","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijrobp.2010.05.007","article-title":"Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma","volume":"81","author":"Li","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib37","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.prro.2019.05.009","article-title":"Comparison of techniques for involved-site radiation therapy in patients with lower mediastinal lymphoma","volume":"9","author":"Everett","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib38","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.radonc.2017.07.033","article-title":"Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma: The impact of proton therapy and\/or deep inspiration breath hold","volume":"125","author":"Rechner","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib39","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib40","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: Field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib41","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2006.05.015","article-title":"Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines","volume":"79","author":"Girinsky","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib42","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/annonc\/13.S1.79","article-title":"The involved field is back: Issues in delineating the radiation field in Hodgkin\u2019s disease","volume":"13","author":"Yahalom","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib43","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ijrobp.2017.04.001","article-title":"Pulmonary toxicity following proton therapy for thoracic lymphoma","volume":"99","author":"Nanda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib44","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ijrobp.2017.05.014","article-title":"Consensus guidelines for implementing pencil-beam scanning proton therapy for thoracic malignancies on behalf of the PTCOG thoracic and lymphoma subcommittee","volume":"99","author":"Chang","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib46","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.ijrobp.2016.08.018","article-title":"Does bleomycin lung toxicity increase the risk of radiation pneumonitis in Hodgkin lymphoma?","volume":"96","author":"Abou Yehia","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib47","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib48","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2016-03-703470","article-title":"Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma","volume":"128","author":"Kumar","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2020.08.055_bib49","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1080\/0284186X.2016.1191665","article-title":"Proton pencil beam scanning for mediastinal lymphoma: Treatment planning and robustness assessment","volume":"55","author":"Zeng","year":"2016","journal-title":"Acta Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301620342024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301620342024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:56:07Z","timestamp":1759744567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301620342024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0360301620342024"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2020.08.055","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Pneumonitis and Outcomes After Mediastinal Proton Therapy for Relapsed\/Refractory Lymphoma: A PTCOG and PCG Collaboration","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2020.08.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}